Boehringer-Ingelheim et al. v. Mankind Pharma, Ltd. et al.

1:21-cv-01766 D. Del. Closed US11090323B2
Get a prior-art report

Infringement action filed 16 Dec 2021 in the United States District Court for the District of Delaware and closed 14 Feb 2023, with US11090323B2 asserted. Recorded basis of termination: consent judgment.

Case recordPatsnap Litigation Data·

Case record

Patent involved
US11090323B2
Application no.
US16/288192
Case no.
1:21-cv-01766
Verdict cause
Infringement action
Court
D. Del.
Court level
District Court
Case region
Delaware
Judge
Colm F. Connolly
Trial level
First instance
Filed – Closed
16 Dec 2021 – 14 Feb 2023
Duration
425 days
Basis of termination
Consent Judgment
Products & marks
Pharmaceutical composition, methods for treating and uses thereof
Validity challenges
None recorded
Source: Patsnap Litigation Data. Case 1:21-cv-01766, United States District Court for the District of Delaware. Open this record in Eureka
Patsnap Eureka

Check this patent against your own product

Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.

Get an FTO claim chart
10,000 free credits to start
Patent at issue
US11090323B2 Active App. US16/288192

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).

Read claims and description in Eureka
Patent standing
Legal status
Active
Granted
17 Aug 2021
Earliest priority
26 Nov 2013
Est. expiry
3 Oct 2034
Validity challenges
None recorded
Licences recorded
None recorded
Classification
A61K31/7048A61K31/7034A61K9/20A61K9/28
Prosecution counsel
VP, IP, LEGAL
US11090323B2 patent drawing, figure 1
Fig. 1 · US11090323B2, from the published patent document
US11090323B2 patent drawing, figure 2
Fig. 2 · US11090323B2, from the published patent document
Source: Patsnap patent data + case record. Bibliographic fields and drawings reproduced from the published patent document. Break down the claims
Parties & counsel

Parties of record

Counsel of record

Source: case record + Patsnap company data. Attorney names appear as recorded in the docket. Compare both portfolios
Outcome

Basis of termination

From the record · verbatim

"IT IS HEREBY ORDERED, ADJUDGED AND DECREED that: 1. This Court has jurisdiction over the subject matter of this action and has personal jurisdiction over the parties. 2. The 957, ’998,°637, and ‘323 patents are valid, enforceable, and infringed by the Mankind ANDA Products. 3. Unless specifically authorized or otherwise modified between the parties, Mankind, including any of its successors and assigns, is enjoined from making, having made, using, selling, offering to sell, or importing the Mankind ANDA Products in the United States, on its own or through any Affiliate, officer, agent, servant, or employee, or through any person in concert or coordination with Mankind or its Affiliates, through and until the expiration of the *957 Patent, the ’998 Patent, the 637 Patent, and the ‘323 Patent including any patent term extension, patent term adjustment, or pediatric exclusivity. If Boehringer becomes entitled to any other regulatory exclusivities that are not referenced herein, Boehringer may apply to the Court for modification of the consent judgment to incorporate such specified exclusivity. Case 1:21-cv-01766-CFC Document 24 Filed 02/14/23 Page 5 of 6 PagelD #: 248 4. This Court retains jurisdiction to enforce performance under this Consent Judgment and any related agreement(s). The Parties agree that, in the event of violation of the terms of this Consent Judgment or any related agreement(s), this Court has personal jurisdiction over the parties and venue for an action to enforce performance under this Consent Judgment, including for a preliminary injunction against the breaching conduct and the Parties hereby waive any and all defenses based on lack of personal jurisdiction or venue, 5. The Complaints in Civil Action Nos. 18-1689-CFC (D. Del.), 19-1498- CFC (D. Del.), and 21-1766-CFC (D. Del.), and all remaining claims, counterclaims, or affirmative defenses in these actions, are dismissed without prejudice and without costs, disbursements, or attorneys’ fees to any party."

Case 1:21-cv-01766 · D. Del. · closed 14 February 2023
Source: case record, verbatim. The quoted paragraph is the basis-of-termination text as filed.

Related cases

Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.

FAQ

Frequently asked questions

What is case 1:21-cv-01766?

1:21-cv-01766 is a patent infringement action brought by Boehringer-Ingelheim against Mankind Pharma, Ltd., filed on 16 Dec 2021 in the United States District Court for the District of Delaware. The case closed on 14 February 2023.

Which patent was asserted in 1:21-cv-01766?

US11090323B2 (“Pharmaceutical composition, methods for treating and uses thereof”), assigned to BOEHRINGER INGELHEIM INTERNATIONAL GMBH, currently active. The record also lists Pharmaceutical composition, methods for treating and uses thereof.

How was case 1:21-cv-01766 terminated?

The recorded basis of termination is consent judgment. The termination text reads: "IT IS HEREBY ORDERED, ADJUDGED AND DECREED that: 1. This Court has jurisdiction over the subject matter of this action and has personal jurisdiction over the parties. 2. The 957, ’998,°637, and ‘323 patents are valid, enforceable, and infringed by the Mankind ANDA Products. 3. Unless specifically authorized or otherwise modified between the parties, Mankind, including any of its successors and assigns, is enjoined from making, having made, using, selling, offering to sell, or importing the Mankind ANDA Products in the United States, on its own or through any Affiliate, officer, agent, servant

What does dismissal without prejudice mean?

A dismissal without prejudice ends this action but leaves the claims alive — the plaintiff may file them again later, subject to the limitation period.

How long did case 1:21-cv-01766 take?

425 calendar days, from filing on 16 Dec 2021 to closure on 14 February 2023.

Who were the attorneys and the judge in 1:21-cv-01766?

Judge Colm F. Connolly presided. Brian P. Egan, Jack B. Blumenfeld and Megan Elizabeth Dellinger are recorded as counsel for plaintiff Boehringer-Ingelheim. Adam V. Orlacchio, Anna Elizabeth Currier, Dipu A. Doshi, James G. Gorman III, Jay P. Lessler and Serena S. Gopal appear for defendant Mankind Pharma.

Answers reproduce fields from the case record for 1:21-cv-01766 and do not constitute legal advice. Ask your own question

General information only. This page reproduces publicly available court docket data for case 1:21-cv-01766 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such. It does not create an attorney-client relationship.

Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.

No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed. The filing of a claim is not a court finding, and a docket marked “closed” does not by itself establish infringement, validity, settlement or a decision on the merits.

No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.

Third-party names and marks. Party, attorney, judge and company names appear for identification only. Company names may be trademarks of their owners; their appearance does not, by itself, imply affiliation with or endorsement by Patsnap.

Patent figures. Any patent drawings shown are reproduced from the identified patent publications to illustrate the cited documents, and do not establish the scope, validity or enforceability of any patent.

Corrections and privacy requests. To report an inaccurate record or attribution, use the “Report an incorrect record” link on this page. For requests concerning your personal information — including, where applicable, the rights to access, rectify, erase, restrict or object to processing — use the “Privacy request” link. We assess requests under applicable law. See our Privacy Policy for details of this processing.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.